Visual Impairment News and Research RSS Feed - Visual Impairment News and Research

The definition of vision impairment by the Centers for Disease Control and Prevention (CDC) says a visually impaired person’s eyesight cannot be corrected to a “normal level”.
Report describes cardiopulmonary arrest in infant following cyclopentolate eyedrops

Report describes cardiopulmonary arrest in infant following cyclopentolate eyedrops

Eyedrops administered to infants as part of routine outpatient retinopathy of prematurity (ROP) screening can have life-threatening consequences. A case report published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) describes cardiopulmonary arrest in a 27-week-old infant following administration of three sets of cyclopentolate 0.2%/phenylephrine 1% (Cyclomydril) eyedrops. [More]
Researchers discover novel population of neutrophils that exhibit enhanced microbial killing activity

Researchers discover novel population of neutrophils that exhibit enhanced microbial killing activity

​Case Western Reserve University researchers have discovered a novel population of neutrophils, which are the body's infection control workhorses. These cells have an enhanced microbial killing ability and are thereby better able to control infection. [More]
Occasional drinking and physically activity linked with reduced risk of developing visual impairment

Occasional drinking and physically activity linked with reduced risk of developing visual impairment

A physically active lifestyle and occasional drinking are associated with a reduced risk of developing visual impairment, according to a study published online this month in Ophthalmology, the journal of the American Academy of Ophthalmology. [More]

PowerVision develops world's first fluid-based accommodating intraocular lens

PowerVision, Inc., a medical device company developing the world's first fluid-based accommodating intraocular lens, today announced that the first 10 patients have received lens implants in its multi-center clinical study assessing the performance of the lens in cataract patients. [More]

Eye health experts across Commonwealth join forces to combat avoidable blindness

A new -7.1 million grant will enable experts from a range of institutions to come together for the first time as the Commonwealth Eye Health Consortium, coordinated by the International Centre for Eye Health at the London School of Hygiene & Tropical Medicine. [More]
NICE guidance influences medical policy towards diabetes prevention nationwide

NICE guidance influences medical policy towards diabetes prevention nationwide

A team of academics from the University of Leicester has been instrumental in shaping National Institute for Health and Care Excellence (NICE) guidance that will influence medical policy towards diabetes prevention nationwide. [More]
Tel Aviv University researchers discover link between sharp vision and the brain's processing speed

Tel Aviv University researchers discover link between sharp vision and the brain's processing speed

Middle-aged adults who suddenly need reading glasses, patients with traumatic brain injuries, and people with visual disorders such as "lazy eye" may have one thing in common --"visual crowding," an inability to recognize individual items surrounded by multiple objects. Visual crowding makes it impossible to read, as single letters within words are rendered illegible. And basic cognitive functions such as facial recognition can also be significantly hampered. Scientists and clinicians currently attribute crowding to a disorder in peripheral vision. [More]
Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare. [More]
Photoreactive compounds open new routes to treatment of neurological diseases

Photoreactive compounds open new routes to treatment of neurological diseases

Photoreactive compounds developed by scientists of Ludwig-Maximilians-Universitaet (LMU) in Munich directly modulate nerve-cell function, and open new routes to the treatment of neurological diseases, including chronic pain and certain types of visual impairment. [More]

Study establishes innovative approaches to improve vision of young children with brain tumor

Robert Avery, DO, MSCE, of Children's National Health System and colleagues are establishing innovative approaches with technology and medication to improve the vision of young children who have visual pathway glioma, a type of brain tumor. [More]

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO). [More]
Moderate aerobic exercise helps preserve nerve cells in retina after damage

Moderate aerobic exercise helps preserve nerve cells in retina after damage

Moderate aerobic exercise helps to preserve the structure and function of nerve cells in the retina after damage, according to an animal study appearing February 12 in The Journal of Neuroscience. The findings suggest exercise may be able to slow the progression of retinal degenerative diseases. [More]

Study: Probability of blindness due to glaucoma has decreased by nearly half

The probability of blindness due to the serious eye disease glaucoma has decreased by nearly half since 1980, according to a study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers speculate that advances in diagnosis and therapy are likely causes for the decrease, but caution that a significant proportion of patients still progress to blindness. [More]

No added benefit from aflibercept, shows study

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein. [More]
FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy. [More]
People with diabetes at risk of developing diabetic macular edema during their lifetime

People with diabetes at risk of developing diabetic macular edema during their lifetime

Despite recent advances in prevention and treatment of most vision loss attributed to diabetes, a new study shows that fewer than half of Americans with damage to their eyes from diabetes are aware of the link between the disease and visual impairment, and only six in 10 had their eyes fully examined in the year leading up to the study. [More]
Researchers investigate several non-invasive methods for measuring intracranial pressure

Researchers investigate several non-invasive methods for measuring intracranial pressure

Do you ever turn your world upside down by standing on your head? After a few minutes you might feel some pressure in your face and around your skull. This is because headstands invert the body's blood flow, pushing more blood toward your head. [More]
FDA accepts Regeneron's EYLEA Injection sBLA for standard review

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema. [More]

Exposure to high-powered blue handheld laser devices can cause serious eye injuries

Exposure for even fractions of a second to high-powered blue handheld laser devices can cause serious eye injuries, according to a study recently released online in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers have concluded that the wide availability of these devices, which are often marketed as toys, could lead to an epidemic of ocular injuries, and greater public awareness and government intervention should be encouraged. [More]

Study finds way to regulate sleep patterns of children with brain disorders

For parents of children with brain disorders or visual impairment, nights can be long and frustrating, leading to even more difficult days as exhaustion takes hold. [More]